Evaxion swings to Q3 2026 net loss of USD 3.54 million year over year
EVAX•
EVAX•Evaxion reported a third-quarter 2026 net loss of USD 3.54 million, compared with year-earlier profit of USD 4.62 million, as revenue fell to nil from USD 7.49 million. Cash was USD 13.3 million at September 30, with runway extended toward the end of 2027.
Evaxion swung to a third-quarter 2026 net loss of USD 3.54 million from a year-earlier profit of USD 4.62 million. Revenue fell to nil from USD 7.49 million, which included out-licensing revenue from EVX-B3.
Cash totaled USD 13.3 million at September 30, 2026, with cash runway extended toward the end of 2027. The company is refocusing on immuno-oncology, prioritizing cancer vaccine development and partnerships. An application for a phase 1 trial of off-the-shelf cancer vaccine EVX-04 remains on track for submission before year-end 2026.